IDH1 and acute myeloid leukemia: Patients with FLT3 mutations (either FLT3-ITD or FLT3-TKD) had significantly higher concordance rates between IDH1/2 LNA-qPCR MRD and AML remission status than patients without FLT3 mutations (96% vs. 71%, p = 0.012).